Stockreport

Leap Therapeutics Announces Collaboration With EORTC to Evaluate DKN-01 in Combination with PD-L1 Cancer Immunotherapy and Chemotherapy In Esophagogastric and Biliary Tract Cancers

Leap Therapeutics, Inc.  (LPTX) 
Last leap therapeutics, inc. earnings: 11/14 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.leaptx.com
PDF CAMBRIDGE, Mass., Sept. 08, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutic [Read more]